Nivolumab plus cabozantinib for advanced renal cell carcinoma-Reference-Cited by-同舟云学术

Nivolumab plus cabozantinib for advanced renal cell carcinoma

Published:2022-12 Issue:39 Volume:18 Page:4351-4359
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Benjamin David J¹^ORCID,Nolla Kyle²,Cella David²

Affiliation:

1. Hoag Family Cancer Institute, 1 Hoag Drive, Building 51, Newport Beach, CA 92663, USA

2. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 625 N. Michigan Avenue, Chicago, IL 60611, USA

Abstract

Advanced renal cell carcinoma (RCC) remains a challenging oncologic disease to treat despite advancements in therapeutics. Nonetheless, the development of tyrosine kinase inhibitors (TKIs) and immunotherapy has drastically altered the treatment landscape for advanced RCC over the past decade. The current standard-of-care treatment for advanced RCC involves combination TKI and immunotherapy regimens including cabozantinib and nivolumab as studied in the CheckMate 9ER trial. This review summarizes the preclinical and clinical evidence that led to the CheckMate 9ER study, as well as pertinent study aspects such as treatment efficacy, adverse events and patient-related outcomes.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2022-0785

Reference49 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Cancer statistics, 2022

3. Renal cell carcinoma

4. Renal cell carcinoma: histological classification and correlation with imaging findings

5. Hereditary Kidney Cancer Syndromes